X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2590) 2590
Publication (353) 353
Book Review (30) 30
Conference Proceeding (7) 7
Book Chapter (4) 4
Magazine Article (4) 4
Dissertation (2) 2
Book / eBook (1) 1
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2194) 2194
cetuximab (2064) 2064
index medicus (1748) 1748
oncology (1351) 1351
female (791) 791
antibodies, monoclonal, humanized (785) 785
cancer (733) 733
antineoplastic agents - pharmacology (725) 725
animals (694) 694
cell line, tumor (694) 694
pharmacology & pharmacy (671) 671
chemotherapy (636) 636
male (634) 634
receptor, epidermal growth factor - antagonists & inhibitors (627) 627
antibodies, monoclonal - pharmacology (576) 576
colorectal neoplasms - drug therapy (569) 569
antineoplastic agents - therapeutic use (562) 562
growth-factor receptor (559) 559
colorectal cancer (538) 538
antibodies, monoclonal - therapeutic use (514) 514
egfr (510) 510
middle aged (495) 495
receptor, epidermal growth factor - metabolism (461) 461
aged (452) 452
mice (446) 446
antineoplastic combined chemotherapy protocols - therapeutic use (399) 399
adult (379) 379
mutation (367) 367
epidermal growth factor (364) 364
colorectal neoplasms - pathology (348) 348
treatment outcome (332) 332
expression (316) 316
therapy (316) 316
monoclonal antibodies (305) 305
tumors (301) 301
care and treatment (299) 299
colorectal neoplasms - genetics (290) 290
1st-line treatment (286) 286
research (285) 285
panitumumab (280) 280
bevacizumab (276) 276
metastasis (271) 271
antibodies, monoclonal - administration & dosage (263) 263
cetuximab - pharmacology (260) 260
head and neck neoplasms - drug therapy (260) 260
cell proliferation - drug effects (259) 259
xenograft model antitumor assays (259) 259
carcinoma, squamous cell - drug therapy (253) 253
mice, nude (248) 248
receptor, epidermal growth factor - genetics (241) 241
monoclonal-antibody (240) 240
metastatic colorectal-cancer (237) 237
medicine & public health (218) 218
drug resistance, neoplasm (217) 217
antineoplastic agents (214) 214
analysis (213) 213
drug therapy (213) 213
signal transduction - drug effects (211) 211
apoptosis - drug effects (205) 205
aged, 80 and over (204) 204
article (203) 203
squamous-cell carcinoma (201) 201
antibodies, monoclonal, humanized - pharmacology (199) 199
epidermal growth factor receptor (198) 198
protein kinase inhibitors - pharmacology (197) 197
ras proteins - genetics (197) 197
antimitotic agents (194) 194
oxaliplatin (193) 193
cancer therapies (192) 192
combination (192) 192
lung-cancer (192) 192
medicine, research & experimental (192) 192
neoplasm metastasis (192) 192
plus cetuximab (192) 192
apoptosis (190) 190
gefitinib (189) 189
colorectal-cancer (187) 187
survival (185) 185
cell lung-cancer (183) 183
fluorouracil (183) 183
neoplasms - drug therapy (183) 183
health aspects (181) 181
proto-oncogene proteins - genetics (179) 179
proto-oncogene proteins p21 (177) 177
squamous cell carcinoma (174) 174
carcinoma (173) 173
carcinoma, squamous cell - pathology (173) 173
quinazolines - pharmacology (173) 173
irinotecan (171) 171
phase-iii trial (170) 170
signal transduction (170) 170
disease-free survival (169) 169
tyrosine kinase inhibitor (169) 169
antineoplastic agents - adverse effects (168) 168
resistance (168) 168
camptothecin - analogs & derivatives (166) 166
pharmacology/toxicology (166) 166
lung neoplasms - drug therapy (165) 165
receptor, epidermal growth factor - immunology (165) 165
cisplatin (164) 164
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2545) 2545
Japanese (19) 19
Spanish (16) 16
Chinese (14) 14
French (10) 10
German (9) 9
Russian (3) 3
Hebrew (2) 2
Finnish (1) 1
Hungarian (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Anti-Cancer Drugs, ISSN 0959-4973, 03/2013, Volume 24, Issue 3, pp. 251 - 259
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | RESISTANCE | EGFR MUTATIONS | KINASE INHIBITORS | ANTITUMOR-ACTIVITY | CHEMOTHERAPY | ZD1839 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology
Journal Article
British Journal of Cancer, ISSN 0007-0920, 2017, Volume 117, Issue 12, pp. 1777 - 1786
Background: Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and... 
Nuclear internalisation | Acquired resistance | IGF-1R | Colorectal cancer | BRAF mutation | colorectal cancer | I RECEPTOR | TUMOR-CELLS | COMBINATION | acquired resistance | INSULIN | nuclear internalisation | MUTATION STATUS | ONCOLOGY | POOR-PROGNOSIS | KRAS | INHIBITOR | TRANSCRIPTION FACTOR | EXPRESSION | Leucovorin - administration & dosage | Receptor, IGF Type 1 - metabolism | Molecular Chaperones - metabolism | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Panitumumab | Drug Resistance, Neoplasm | Male | Protein Inhibitors of Activated STAT - metabolism | Protein Transport - drug effects | Cell Nucleus - metabolism | Colorectal Neoplasms - drug therapy | Protein Inhibitors of Activated STAT - genetics | Camptothecin - administration & dosage | Camptothecin - analogs & derivatives | Cell Survival - drug effects | Bevacizumab - administration & dosage | Antibodies, Monoclonal - pharmacology | HCT116 Cells | Curcumin - pharmacology | Molecular Chaperones - genetics | Pyrimidines - pharmacology | Dasatinib - pharmacology | Signal Transduction - drug effects | Sorafenib | Fluorouracil - pharmacology | Niacinamide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Molecular Targeted Therapy | Organoplatinum Compounds - pharmacology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Oxaliplatin | Female | Antineoplastic Agents - pharmacology | Gene Silencing | Fatty Acids, Unsaturated - pharmacology | HT29 Cells | Pyrroles - pharmacology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Cetuximab - administration & dosage | Aged | Phenylurea Compounds - pharmacology | Niacinamide - pharmacology | Colorectal Neoplasms - pathology | Immunohistochemistry | Medical research | Cell survival | Insulin-like growth factor I | RNA-mediated interference | Colorectal carcinoma | Chemoresistance | Clinical trials | Insulin-like growth factors | Metastasis | Insulin | Patients | Survival | Metastases | Proteins | SUMO protein | Chemotherapy | Cell lines | Monoclonal antibodies | Tumors | Cancer | Translational Therapeutics
Journal Article
Nature Communications, ISSN 2041-1723, 03/2017, Volume 8, Issue 1, p. 14768
Journal Article
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2016, Volume 22, Issue 6, pp. 624 - 631
Cetuximab is a monoclonal antibody that is effective in the treatment of metastatic colorectal cancer (mCRC). Cetuximab blocks epidermal growth factor receptor... 
MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | PLUS IRINOTECAN | EFFICACY | BIOCHEMISTRY & MOLECULAR BIOLOGY | METASTATIC COLORECTAL-CANCER | CELL BIOLOGY | CALRETICULIN EXPOSURE | COLON-CANCER | BRAF MUTATION | POOLED ANALYSIS | ENDOPLASMIC-RETICULUM | KRAS | Leucovorin - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Dendritic Cells - immunology | Humans | Cell Death - immunology | X-Box Binding Protein 1 - drug effects | Endoplasmic Reticulum Stress - immunology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Fluorouracil - administration & dosage | Calreticulin - drug effects | Calreticulin - metabolism | Camptothecin - administration & dosage | Dendritic Cells - drug effects | Indoles - pharmacology | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Camptothecin - analogs & derivatives | Disease Models, Animal | Phagocytosis - drug effects | X-Box Binding Protein 1 - immunology | Endoplasmic Reticulum Stress - drug effects | Antibodies, Monoclonal - pharmacology | HCT116 Cells | Phagocytosis - immunology | Cetuximab - pharmacology | Sulfonamides - pharmacology | Unfolded Protein Response | HT29 Cells | Animals | Colorectal Neoplasms - immunology | Proto-Oncogene Proteins B-raf - genetics | X-Box Binding Protein 1 - metabolism | Cell Line, Tumor | Mice | Pyridones - pharmacology | Physiological aspects | Genetic aspects | Immune response | Research | Drug therapy | Colorectal cancer | Care and treatment | Usage | Chemotherapy | Epidermal growth factor | Cell death | Analysis | Endoplasmic reticulum | Cancer | Monoclonal antibodies | Apoptosis | Immune system
Journal Article
Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon... 
PANITUMUMAB | TARGET | CETUXIMAB | MELANOMA | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PAPILLARY THYROID-CARCINOMA | KRAS | METASTATIC COLORECTAL-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 2005, Volume 70, Issue 11, pp. 1568 - 1578
Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death worldwide. In light of the very poor 5 year survival new therapeutic... 
Insulin-like growth factor receptor | Tarceva | EGF | Chemoprevention | IGF | Doxorubicin | Epidermal growth factor receptor | Statins | Cisplatin | Erbitux | Erbitux (TM) | UNITED-STATES | COA REDUCTASE INHIBITOR | APOPTOSIS | FACTOR RECEPTOR FAMILY | epidermal growth factor receptor | ANTIBODY | insulin-like growth factor receptor | FACTOR-ALPHA | P53 | chemoprevention | statins | Tarceva (TM) | PHARMACOLOGY & PHARMACY | doxorubicin | cisplatin | HEPATOMA-CELL LINES | CARCINOMA | EXPRESSION | Erlotinib Hydrochloride | Fatty Acids, Monounsaturated - pharmacology | Apoptosis - drug effects | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Indoles - pharmacology | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cetuximab | Drug Evaluation, Preclinical | Drug Therapy, Combination | Antibodies, Monoclonal - pharmacology | Liver Neoplasms - drug therapy | Tyrphostins - pharmacology | Cisplatin - pharmacology | Cell Division - drug effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Cell Cycle - drug effects | Quinazolines - pharmacology | Doxorubicin - pharmacology | Tyrosine | Anthracyclines | Care and treatment | Growth | Immunoglobulin G | Peptide hormones | Prevention | Liver cancer | Epidermal growth factor | Monoclonal antibodies | Tumor proteins | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2016, Volume 11, Issue 6, p. e0156540
Background Terpinen-4-ol, a naturally occurring monoterpene is the main bioactive component of tea-tree oil and has been shown to have many biological... 
CELLS | PERILLYL ALCOHOL | MULTIDISCIPLINARY SCIENCES | GENE-THERAPY | COMPONENT | CD24 | TEA TREE OIL | Gastrointestinal Neoplasms - drug therapy | Humans | Tea Tree Oil - chemistry | Antineoplastic Agents, Phytogenic - chemistry | Cetuximab - pharmacology | Deoxycytidine - pharmacology | Organoplatinum Compounds - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Terpenes - pharmacology | Xenograft Model Antitumor Assays | Gastrointestinal Neoplasms - pathology | Terpenes - chemistry | Animals | Oxaliplatin | Erlotinib Hydrochloride - pharmacology | Cell Line, Tumor | Fluorouracil - pharmacology | Mice | Antineoplastic Agents, Phytogenic - pharmacology | Deoxycytidine - analogs & derivatives | Gastrointestinal Neoplasms - metabolism | Antimitotic agents | Usage | Chemotherapy | Gastrointestinal cancer | Patient outcomes | Colorectal cancer | Dosage and administration | Drug therapy | Antineoplastic agents | Essences and essential oils | Cancer | Cell proliferation | Flow cytometry | Terpinene | Gemcitabine | Laboratories | Colorectal carcinoma | Xenotransplantation | Lung cancer | Cancer therapies | Anticancer properties | Biological effects | Gastroenterology | Xenografts | Cell cycle | Biocompatibility | Inhibition | Pancreas | Gastric cancer | Epidermal growth factor receptors | Melanoma | Pharmacology | Gene expression | Chemical compounds | Molecular chains | Disease prevention | Cell death | Pancreatic cancer | Monoclonal antibodies | Oils & fats | Antitumor activity | Light microscopy | Gene therapy | Molecular biology | Prostate cancer | Prostate | Tumors | Apoptosis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4769 - 4777
In patients with metastatic colorectal cancer, the predictive value of KRAS mutational status in the selection of patients for treatment with anti-epidermal... 
K-RAS MUTATIONS | RESECTED STAGE-I | PROGNOSTIC IMPACT | ONCOLOGY | RANDOMIZED PHASE-III | EML4-ALK FUSION GENE | BRONCHIOLOALVEOLAR-CARCINOMA | 1ST-LINE TAXANE/CARBOPLATIN | MOLECULAR PREDICTORS | GENE COPY NUMBER | ONCOGENE ACTIVATION | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Predictive Value of Tests | Receptor, Epidermal Growth Factor - genetics | Translocation, Genetic | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Paclitaxel - pharmacology | Microtubule-Associated Proteins - genetics | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | ras Proteins - metabolism | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Patient Selection | Antibodies, Monoclonal, Humanized | Protein-Tyrosine Kinases - genetics | Receptor, Epidermal Growth Factor - metabolism | Serine Endopeptidases - genetics | Biomarkers, Tumor - metabolism | Cell Cycle Proteins - genetics | Antineoplastic Agents - pharmacology | Cetuximab | Precision Medicine | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Proto-Oncogene Proteins - genetics | Clinical Trials as Topic | Cisplatin - pharmacology | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives
Journal Article